ITCI 241018 80.00C (ITCI241018C80000) Stock Options, News & Quotes

US OptionsDetailed Quotes

ITCI241018C80000

Watchlist

0.55
-0.03-5.17%

15min DelayClose Sep 27 16:00 ET

0.55High0.55Low

Intraday

5D
Daily

News

Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Moomoo NewsSep 24 08:31 ET · Ratings
Jefferies Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)
TipRanksSep 24 08:16 ET · Ratings
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Dow JonesSep 16 12:00 ET · Ratings
Express News | Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
BenzingaSep 16 11:50 ET
Intra-Cellular Therapies' (NASDAQ:ITCI) Investors Will Be Pleased With Their Fantastic 798% Return Over the Last Five Years
Simply Wall StSep 16 11:31 ET
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Seeking AlphaSep 15 15:48 ET · Ratings

Comments

Meltyy

Apr 1 02:47

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$Hutchmed (China) (HCM.US)$ Phase 3
$Viracta Therapeutics (VIRX.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Marinus Pharmaceuticals (MRNS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3...

Moomoo AI

Mar 27 10:03

Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.

Market Sentiment Around Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Meltyy

Mar 21 21:48

Mental Health Biotech Catalyst Watchlist

$Vanda Pharmaceuticals (VNDA.US)$ PDUFA
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$Bristol-Myers Squibb (BMY.US)$ PDUFA
$Alzamend Neuro (ALZN.US)$ Phase 2
$Alzamend Neuro (ALZN.US)$ Phase 2a

Meltyy

Feb 21 22:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer (PFE.US)$ Phase 3
$Palatin Technologies (PTN.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ $Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$...

Moomoo AI

Feb 14 08:15

The market seems optimistic about Intra-Cellular Therapies, Inc. given its strong revenue growth and share price momentum. It's recommended to take a closer look at this stock.

Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Have Earned a 39% CAGR Over the Last Five Years